Despite being one of the common diseases, the treatment options for nonalcoholic steatohepatitis (NASH) are still limited. Recently, Gawrieh et al. demonstrated significant improvement in liver enzymes and liver fat content (LFC) in nonalcoholic fatty liver disease (NAFLD)/NASH patients treated with saroglitazar (1). It's indeed an interesting attempt to exploit new avenues for treating NAFLD by using a dual PPAR-α/γ agonist, currently used in India for diabetic dyslipidemia (2). However, there are a few concerns in the current trial that require attention.